To date, most literature suggested that LINC00511 was aberrantly upregulated in malignant tumors and its high expression correlated with poor survival of patients with glioma [7], ovarian cancer [8], breast cancer [9,10], cervical cancer [11,12], osteosarcoma [13], lung cancer [14], gastric cancer [22], hepatocellular carcinoma [15], renal cell cancer [18] or pancreatic cancer [19]. Here, LINC00511 is linked to osteosarcoma.